Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...